分组1 - TriSalus Life Sciences, Inc. reported a quarterly loss of $0.27 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.22, and compared to a loss of $0.21 per share a year ago, indicating an earnings surprise of -22.73% [1] - The company posted revenues of $11.21 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.52%, and this represents an increase from year-ago revenues of $7.36 million [2] - TriSalus Life Sciences, Inc. shares have declined approximately 28.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] 分组2 - The earnings outlook for TriSalus Life Sciences, Inc. is uncertain, with current consensus EPS estimates of -$0.16 on $11.38 million in revenues for the coming quarter and -$0.86 on $44.31 million in revenues for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 42% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact the stock's performance [8]

Trisalus Life Sciences (TLSI) Q2 2025 Earnings Call August 12, 2025 04:30 PM ET Speaker0Good afternoon, and welcome to Triphala's Life Sciences Second Quarter twenty twenty five Earnings Conference Call. Currently, all participants are in a listen only mode. Following management's prepared remarks, we will hold a question and answer session. As a reminder, this call is being recorded for replay purposes. I will now turn the call over to Jeremy Feffer, managing director with Life SciFi Advisor.Please go ahea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Commission file number 001-39813 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ (State ...

DENVER – August 12, 2025 - TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operation update. "TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical adoption of our ...

Company Overview - TriSalus Life Sciences, Inc. held its Q1 2025 Earnings Conference Call on May 15, 2025, featuring key participants including the President and CEO, CFO, and Medical Director [1][3][4]. Financial Results - The company released its financial results for the quarter ended March 31, 2025, which were discussed in detail during the call [4]. Strategic Direction - The President and CEO provided an overview of the company's first quarter results and outlined the strategy for the remainder of the year [4].

Company Performance - TriSalus Life Sciences, Inc. reported a quarterly loss of $0.33 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, representing an earnings surprise of -65% [1] - The company posted revenues of $9.17 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.04%, but showing an increase from $6.46 million in the same quarter last year [2] - Over the last four quarters, the company has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - TriSalus Life Sciences, Inc. shares have declined approximately 2.2% since the beginning of the year, while the S&P 500 has gained 0.2% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $10.69 million, and for the current fiscal year, it is -$0.60 on revenues of $44.3 million [7] - The outlook for the Medical - Products industry, to which TriSalus belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact the stock's performance [8]

Trisalus Life Sciences (TLSI) Q1 2025 Earnings Call May 15, 2025 08:00 AM ET Company Participants Alexandra Grossman - Associate DirectorMary Szela - CEO, President & DirectorJames Young - CFORichard Marshall - Medical DirectorSuraj Kalia - Managing DirectorWilliam Plovanic - Managing Director - Equity Research Conference Call Participants Justin Walsh - Director & Research AnalystRoss Osborn - AnalystFrank Takkinen - Senior Research AnalystJason Wittes - Managing Director & Senior Research Analyst Operator ...

Trisalus Life Sciences (TLSI) Q1 2025 Earnings Call May 15, 2025 08:00 AM ET Speaker0 Good morning and welcome to the Trisales Life Sciences First Quarter twenty twenty five Earnings Conference Call. Currently, all participants are on a listen only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Alex Grossman, associate director with LifeSci Advisors. Please ...

Revenue and Sales Performance - TriSalus reported a revenue increase driven primarily by sales of its PEDD infusion systems, particularly the TriNav, with a gross margin that allows for substantial funding of growth and R&D [227][230]. - Revenue increased by $2.7 million, or 42.0%, for the three months ended March 31, 2025, compared to the same period in 2024, primarily due to increased sales of TriNav [239]. Product Development and Clinical Trials - The company launched the TriNav LV Infusion System and TriGuide Guiding Catheter in 2024, expanding its PEDD device portfolio to optimize therapeutic delivery for larger vessels [215][216]. - A registry study called PROTECT aims to enroll 100 patients and is expected to expand the addressable market by approximately 50,000 procedures, representing an incremental $400 million market opportunity [217]. - The company completed Phase I clinical trials for nelitolimod and is exploring partnerships for further development, with data expected in 2025 [218]. - The MDACC Agreement was modified and extended to include a sixth year, enhancing collaboration for ongoing clinical studies [222]. Financial Position and Cash Flow - Cash and cash equivalents were approximately $13.0 million at March 31, 2025, with a minimum cash requirement increased from $5.0 million to $10.0 million [250]. - Net cash used in operating activities was $4.5 million for the three months ended March 31, 2025, compared to $10.9 million for the same period in 2024 [251]. - Net cash provided by financing activities was $9.7 million for the three months ended March 31, 2025, primarily from the First Delayed draw under the OrbiMed Credit Agreement [256]. Expenses and Losses - Gross profit increased by $2.2 million, or 39.8%, for the three months ended March 31, 2025, with gross margin decreasing to 83.7% from 85.0% [241]. - Research and development expenses decreased by $2.5 million, or 43.6%, for the three months ended March 31, 2025, primarily due to reduced clinical trial expenses [242]. - General and administrative expenses increased by $0.3 million, or 7.4%, for the three months ended March 31, 2025, mainly due to professional services related to filing and audit expenses [245]. - Net loss available to common stockholders was $10.4 million for the three months ended March 31, 2025, compared to a net loss of $13.2 million for the same period in 2024 [238]. Funding and Capital Requirements - TriSalus secured a $10 million loan under the OrbiMed Credit Agreement, contingent on achieving a $30 million revenue base [221]. - The company anticipates gross proceeds of approximately $22 million from a private placement of 5.5 million shares at $4.00 per share, closing on May 2, 2025 [225]. - The company expects to finance its cash needs through a combination of securities offerings, debt financings, collaborations, strategic alliances, and licensing arrangements [260]. - There is substantial doubt regarding the company's ability to continue as a going concern as of March 31, 2025, due to its reliance on generating sufficient cash flows or obtaining additional capital [263]. - If the company is unable to raise additional capital, it may have to delay or terminate product development efforts [261]. - The company may face dilution of existing ownership interests if it raises additional capital through equity or convertible debt securities [260]. Regulatory and Compliance Matters - TriSalus received a permanent HCPCS code for the TriNav Infusion System effective January 1, 2024, which may enhance reimbursement clarity and support sales [214]. - The expiration of the TPT payment program in December 2023 poses a risk to maintaining current pricing and gross margins for TriNav [219]. - The company is subject to affirmative and restrictive covenants under the OrbiMed Credit Agreement, which may limit its operational flexibility [260]. - The company does not currently have any off-balance sheet financing arrangements or relationships with unconsolidated entities [266]. - The company’s critical accounting policies have not changed significantly during the three months ended March 31, 2025, compared to the previous year [267]. Other Financial Liabilities - The fair value of the SEPA, warrant, and revenue base redemption liabilities changed by $3.4 million, resulting in a loss of $0.8 million for the three months ended March 31, 2025 [247]. - The company has paid Dynavax $12.0 million as of March 31, 2025, with potential additional payments of up to $158 million upon achieving certain milestones related to nelitolimod [265]. - The company may be required to pay up to $80 million upon achieving certain commercial milestones for nelitolimod, subject to obtaining marketing approval [265].

[Securities Purchase Agreement](index=1&type=section&id=SECURITIES%20PURCHASE%20AGREEMENT) This Securities Purchase Agreement outlines the terms for a private placement of 5,500,000 common shares at $4.00 each, totaling $22,000,000, between TriSalus Life Sciences, Inc. and investors [Definitions](index=1&type=section&id=1.%20Definitions) This section defines key terms like "Material Adverse Effect" and "Transaction Agreements" for precise interpretation of the agreement - Defines **"Material Adverse Effect"** as a significant adverse impact on the Company's business, financial condition, or ability to fulfill its obligations under the agreement[34](index=34&type=chunk) - Defines **"Transaction Agreements"** to include this Securities Purchase Agreement and the associated Registration Rights Agreement[53](index=53&type=chunk) [Purchase and Sale of Shares](index=5&type=section&id=2.%20Purchase%20and%20Sale%20of%20Shares) This section outlines the core transaction terms, including the sale of common stock at a fixed price and closing logistics Transaction Details | Metric | Value | | :--- | :--- | | Price per Share | $4.00 | | Total Shares Sold | 5,500,000 | | Total Purchase Price | $22,000,000.00 | - The closing of the purchase and sale is scheduled to occur remotely no later than the **fifth business day** after the agreement date[55](index=55&type=chunk) - At closing, investors will pay the aggregate purchase amount via wire transfer, and the Company will issue the shares in book-entry form, free of most restrictive legends[55](index=55&type=chunk) [Representations and Warranties of the Company](index=6&type=section&id=3.%20Representations%20and%20Warranties%20of%20the%20Company) The Company provides extensive representations and warranties to investors, covering SEC filings, capitalization, and compliance, forming a factual baseline - The Company warrants that its **SEC filings** are accurate, compliant with regulations, and do not contain any material misstatements or omissions[66](index=66&type=chunk) - The Company confirms its Common Stock is listed on the **Nasdaq Global Market** under the symbol "TLSI" and it is in compliance with all listing requirements[80](index=80&type=chunk) - The Company represents that it has not engaged in general solicitation for this offering and that the transaction is exempt from registration under the Securities Act, assuming the accuracy of investor representations[88](index=88&type=chunk) - The Company represents it has entered into Support Agreements with holders of more than **50%** of its outstanding Preferred Stock, related to a planned Exchange Offer[100](index=100&type=chunk) [Representations and Warranties of Each Investor](index=17&type=section&id=4.%20Representations%20and%20Warranties%20of%20Each%20Investor) Each investor represents their status as an accredited investor, acknowledging investment risks and intent to hold shares for investment - Each Investor represents that it is an **"accredited investor"** or **"qualified institutional buyer"** with the financial knowledge to evaluate the investment[107](index=107&type=chunk) - Investors acknowledge that the shares are not registered under the Securities Act and are subject to transfer restrictions, understanding they must be held indefinitely unless registered or an exemption is available[112](index=112&type=chunk) - Investors confirm they are not purchasing shares as a result of any general solicitation or public advertising[117](index=117&type=chunk) [Covenants](index=22&type=section&id=5.%20Covenants) This section outlines ongoing obligations, including the Company's commitment to file Form 8-K, maintain Nasdaq listing, and adhere to equity sale restrictions - The Company must file a Current Report on **Form 8-K** by 9:00 a.m. New York City time on the first business day following the agreement to disclose the transaction and any material non-public information[124](index=124&type=chunk) - For **60 days** after closing, the Company agrees not to issue additional shares of Common Stock or equivalents, with certain exceptions such as for employee compensation plans or the planned Exchange Offer[137](index=137&type=chunk) - The Company agrees to indemnify and hold harmless the Investors from losses arising from any breach of its representations, warranties, or covenants in the agreement[133](index=133&type=chunk) [Conditions of Closing](index=26&type=section&id=6.%20Conditions%20of%20Closing) This section specifies conditions for closing, including accurate Company representations, absence of material adverse effects, and receipt of the full purchase price - A key condition for the Investors' obligation to close is that no event constituting a **Material Adverse Effect** has occurred since the agreement date[142](index=142&type=chunk) - The Company must deliver a legal opinion from its counsel, **Cooley LLP**, to the Investors and the Placement Agent at closing[150](index=150&type=chunk) - The Company's obligation to close is conditioned upon receiving the **full purchase price** from each Investor via wire transfer[155](index=155&type=chunk) [Termination](index=28&type=section&id=7.%20Termination) This section outlines circumstances for agreement termination prior to closing, including mutual consent or if closing does not occur within **five business days** - The agreement can be terminated by either the Company or an Investor if the Closing does not occur on or prior to the **fifth business day** following the date of the agreement[156](index=156&type=chunk) - Termination is also possible by **mutual written consent** of the Company and the Investor Majority[155](index=155&type=chunk)[157](index=157&type=chunk) [Miscellaneous Provisions](index=29&type=section&id=8.%20Miscellaneous%20Provisions) This section contains standard legal clauses governing agreement interpretation and enforcement, covering governing law, jurisdiction, and several investor obligations - The agreement is governed by the laws of the **State of New York**, and the parties submit to the jurisdiction of courts in Manhattan, waiving the right to a jury trial[165](index=165&type=chunk)[167](index=167&type=chunk) - The obligations of each Investor are **several and not joint**, meaning no Investor is responsible for the performance of any other Investor[181](index=181&type=chunk) - The Placement Agent (**Canaccord Genuity LLC**) is an intended third-party beneficiary of certain representations and warranties made by the Company and the Investors[38](index=38&type=chunk)[179](index=179&type=chunk) [Exhibits](index=61&type=section&id=Exhibits) The exhibits provide supplementary information, including investor commitments in Exhibit A and the Registration Rights Agreement in Exhibit B Investor Commitments (Exhibit A) | Investor Name | Shares | Aggregate Purchase Price | | :--- | :--- | :--- | | Alyeska Master Fund, LP | 557,500 | $2,230,000.00 | | Broadfin Holdings LLC | 125,000 | $500,000.00 | | Lytton-Kambara Foundation | 400,000 | $1,600,000.00 | | Nantahala Capital Partners LP | 457,086 | $1,828,344.00 | | Blackwell Partners LLC – Series A | 817,614 | $3,270,456.00 | | Pinehurst Partners, L.P. | 500,000 | $2,000,000.00 | | Special Situations Funds (Aggregate) | 1,250,000 | $5,000,000.00 | | ... (Other Investors) | ... | ... | | **TOTAL:** | **5,500,000** | **$22,000,000.00** | - Exhibit B confirms that a **Registration Rights Agreement** will be executed, providing investors with rights to have their shares registered with the SEC for future public sale[243](index=243&type=chunk)[3](index=3&type=chunk)